TRVI Latest Headlines

Trevi Therapeutics: Buy Rating Reaffirmed as Chronic-Cough Pipeline Advances; $28 Price Target Unchanged

at www.tipranks.com (Tue, 10-Nov 10:37 AM)

Trevi Therapeutics (TRVI) Gets a Buy from Morgan Stanley

at www.tipranks.com (Tue, 10-Nov 8:16 AM)

Trevi Therapeutics (TRVI) Receives a Buy from Oppenheimer

at www.tipranks.com (Tue, 10-Nov 7:55 AM)

Cantor Fitzgerald Reaffirms Their Buy Rating on Trevi Therapeutics (TRVI)

at www.tipranks.com (Tue, 10-Nov 7:55 AM)

Needham Sticks to Its Buy Rating for Trevi Therapeutics (TRVI)

at www.tipranks.com (Tue, 10-Nov 7:35 AM)

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Definium Therapeutics (DFTX) and Allogene Therapeutics (ALLO)

at www.tipranks.com (Tue, 10-Nov 7:31 AM)

Trevi Therapeutics GAAP EPS of -$0.13 beats by $0.01

at seekingalpha.com (Mon, 9-Nov 5:01 PM)